Abbott, GSK to Develop PCR-Based Molecular Dx to Select Patients for Trial Skin Cancer Therapy

Abbott and GSK will develop and commercialize a PCR test for the MAGE-A3 biomarker using Abbott's m2000 automated real-time PCR system.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.